BioSpace News Archive

Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Douglas Kerr, M.D., Ph.D., to its board of directors.

Worldwide revenue of $92.5 million for the first quarter 2021, representing an increase of 2.0% from the prior year period Net income of $9.0 million for the first quarter 2021, compared to net income of $3.3 million in the prior year period

– Topline clinical data from SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis expected in mid-2021, microbiome biomarker data anticipated in H2 2021 – – Ongoing enrollment in SER-109 open label study for recurrent C. difficile infection; On track to achieve 300 subject enrollment target in Q3 2021 –

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it received a Paragraph IV Notice Letter regarding the submission by a generic manufacturer of an Abbreviated New Drug Application

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of Sales, effective May 10, 2021.

Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary Chemotype Evolution (CE) technology to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today U.S. Food and Drug Administration (FDA) clearance of an IND application for CT-868, Carmot’s dual GLP-1 and GIP receptor modulator.

Mize shares insights from a real-world journey to transform and unify access to service information globally at the Field Service Medical Virtual Event May 4-5, 2021.

Progenity survey showsmore women know their baby’s “fruit size” than the key indicator of a common pregnancy complication

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the intravenous formulation (IV) of TPOXX®.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on May 11, 2021.